This episode explores hormonal cancer therapy as the pharmacology of signal withdrawal. Many cancers-particularly of the breast, prostate, and endometrium-are driven less by unchecked division and more by sustained hormonal instruction. We examine how manipulating endocrine signals can slow, stabilise, or even reverse tumour progression without the cyto…

This episode explores pathway-targeted cancer therapies as the pharmacology of precision with consequences. Monoclonal antibodies, small-molecule kinase inhibitors, and pathway disruptors are designed to strike specific molecular drivers of malignancy-often with dramatic early responses. We unpack oncogenic signalling, addiction to pathways, and biomark…

This episode focuses on cytotoxic chemotherapy as the pharmacology of turning speed against itself. Cytotoxic drugs do not recognise cancer by identity, but by behaviour-targeting cells that divide rapidly, repair poorly, and fail to pause. We explore antimetabolites, alkylating agents, platinum compounds, antitumour antibiotics, and mitotic inhibitors …

This episode introduces cancer pharmacotherapy as the discipline of constrained aggression. Unlike infections, cancer arises from the host’s own cells-meaning therapy must discriminate between malignant growth and essential renewal. We explore the fundamental principles that govern oncology treatment: cell-cycle vulnerability, therapeutic index, combina…

This episode explores HIV pharmacology as the discipline of durable containment. HIV integrates into host DNA, mutates rapidly, and rebounds when pressure slips-making cure elusive but control achievable. We trace the viral life cycle to understand why combination therapy is essential, how high genetic barriers protect efficacy, and why adherence is the…

This episode focuses on hepatitis B and C as the pharmacology of containment and clearance. Unlike acute lytic infections, hepatitis viruses persist quietly within hepatocytes, driving chronic inflammation, fibrosis, and long-term risk. We explore the distinct therapeutic logics of HBV suppression versus HCV eradication-nucleos(t)ide analogues that rest…

This episode reframes antiviral therapy as the pharmacology of interruption. Viruses lack cell walls, metabolism, and independent machinery; they succeed by hijacking ours. Effective drugs therefore target steps in replication-entry, uncoating, genome synthesis, assembly, and release-while sparing host function as much as possible. We explore nucleos(t)…

This episode explores antifungal agents as the pharmacology of narrow discrimination. Fungi are eukaryotes-biologically closer to us than bacteria-so effective therapy depends on exploiting small but crucial differences in cell membranes, cell walls, and replication machinery. We examine ergosterol synthesis and binding, cell wall β-glucan inhibition, n…

This episode explores tuberculosis, non-tuberculous mycobacterial disease (including MAC), and leprosy as the pharmacology of endurance. Mycobacteria grow slowly, hide within host cells, and possess formidable cell walls-forcing therapy to be prolonged, multi-drug, and meticulously coordinated. We examine cell wall synthesis inhibition, RNA polymerase t…

This episode explores antibiotics that target bacterial protein synthesis as the pharmacology of industrial disruption. Rather than collapsing structural walls, these agents interfere with ribosomal function-stalling, misreading, or prematurely terminating protein assembly. We examine tetracyclines, macrolides, lincosamides, chloramphenicol, streptogram…